While AML can manifest as a de novo condition in FA, our study reveals that AML commonly evolves from a preceding phase of MDS, characterized by a gradual increase in blast cell population over several months or years, not only in FA patients but also in those with NHEJ1 deficiency and DC. The gene discussed is NHEJ1; the disease is acute myeloid leukemia.